NCT01051063 - Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2009

Primary Completion Date

April 26, 2016

Study Completion Date

April 26, 2016

Conditions

Leukaemia, Myelocytic, Acute

Interventions

BIOLOGICAL

GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A

Intramuscular injection

Trial Locations (22)

12200

GSK Investigational Site, Berlin

13273

GSK Investigational Site, Marseille

18057

GSK Investigational Site, Rostock

21201

GSK Investigational Site, Baltimore

26133

GSK Investigational Site, Oldenburg

33604

GSK Investigational Site, Pessac

37232

GSK Investigational Site, Nashville

38043

GSK Investigational Site, Grenoble

44093

GSK Investigational Site, Nantes

48149

GSK Investigational Site, Münster

49933

GSK Investigational Site, Angers

55131

GSK Investigational Site, Mainz

59037

GSK Investigational Site, Lille

69120

GSK Investigational Site, Heidelberg

69495

GSK Investigational Site, Pierre-Bénite

75475

GSK Investigational Site, Paris

79106

GSK Investigational Site, Freiburg im Breisgau

89081

GSK Investigational Site, Ulm

91054

GSK Investigational Site, Erlangen

97080

GSK Investigational Site, Würzburg

01655

GSK Investigational Site, Worcester

01307

GSK Investigational Site, Dresden